Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody F(ab')2 Fragments (INOSARS) for Adult Patients With Mild COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 7, 2021

Primary Completion Date

August 1, 2022

Study Completion Date

August 1, 2022

Conditions
COVID-19
Interventions
DRUG

Placebo

Placebo of saline solution of equal volume and infusion. Content of the infusion bag and tubing will be concealed with opaque covering.

DRUG

Anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments (INOSARS)

INOSARS is a polyvalent passive immunization based on anti-SARS-CoV-2 immunoglobulin F(ab')2 fragments from hyperimmune equine serum. Inactive ingredients: water for injection, sodium chloride and less than 10% of total protein content.

Trial Locations (1)

64718

Hospital San José, Tec de Monterrey, Monterrey

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Inosan Biopharma

INDUSTRY

lead

TecSalud Investigación Clínica

OTHER